News, Scientific publications and Events

News on NOVENTURE participation in 2018 EAACI in Munich

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce its presence in the allergy field thanks to its medical device RHINOSECTAN® intended to control and prevent symptoms of rhinitis and rhinosinusitis, especially those of allergic origin. EAACI is the Europe’s largest medical association in the field of allergy and clinical immunology and it offers a unique chance to learn about latest discovery as it gathers KOLs from around the world.

Gastroenterology News TASECTAN® TASECTAN® DUO XILAPLUS®

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.

Barrier Technology Uro-ginecology Scientific Publication

New scientific evidence reinforces usefulness of the mucoprotective approach

M. Lanza1, I. Paterniti1, M. Campolo1 ,G. Casili1 , A. Filippone1,A. Peritore1, S. Cuzzocrea1,2 ,E. Esposito1 1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina- Messina, Italy 2Department of Pharmacological and Physiological Science, Saint Louis University, South Grand Blvd St. Louis, Missouri, USA

A team of investigators led by Prof Cuzoccrea at the University of Messina has demonstrated in an in vivo study the beneficial effect on candida albicans infection of a medical device consisting of pea protein and grape seed extract due to their protective barrier properties. The results are new evidence of the muco-protective effects of some natural polymers against mucosa invasion by microorganisms.